We present here new evidence on the use of CTX prophylaxis for patients on ART, from observational data from the DART trial in Uganda and Zimbabwe. Outcomes were compared between patients on ART who received CTX, and those on ART who did not. CTX prophylaxis reduced mortality by 35% overall. The reduction was similar for those with CD4 counts over and those under 200. In the first 4 weeks of initiating ART the reduction was even more marked, at 58%, but this effect declined to 5% in weeks 68-72, with no effect after 72 weeks. The research found that CTX prophylaxis continued to reduce mortality for up to 72 weeks in patients on ART, irrespective of CD4 count.
Evidence For Action Briefing Paper Issue 07, January 2011, 4 pp.
Briefing Paper No. 7. Reducing early mortality on ART